All specialtiesGastroenterology
Gastroenterology Evidence Evolution
5 evidence evolution narratives tracing how landmark trials and guideline updates reshaped gastroenterology practice.
9.11998-2024
IBD Biologic Selection
The expanding therapeutic arsenal
5-ASA/steroids → infliximab (ACT/ACCENT) → vedolizumab (GEMINI) → ustekinumab (UNITI) → JAK (tofacitinib/upadacitinib)
ACTACCENTGEMINIUNITIOCTAVEU-ACHIEVE
Read evolution
9.21990-2024
H. pylori Eradication
Overcoming resistance
Triple therapy → resistance rise → bismuth quadruple → vonoprazan (PHALANX)
MaastrichtPHALANXOPTIMAZE
Read evolution
9.32005-2024
MASLD/NASH Pharmacotherapy
First approved therapies at last
No approved drugs → vitamin E (PIVENS) → semaglutide (STEP-NASH) → resmetirom (MAESTRO-NASH)
PIVENSREGENERATEMAESTRO-NASH
Read evolution
9.41990-2024
Colorectal Cancer Screening Evolution
Earlier, smarter, AI-assisted
Sigmoidoscopy → colonoscopy → FIT → age 45 start → AI-assisted colonoscopy
NordICCUSPSTF 2021GI Genius
Read evolution
9.52005-2023
Acute Pancreatitis Fluid Management
The end of aggressive hydration
NPO + aggressive IV → WATERFALL moderate fluids (2022) → early feeding → paradigm reversal
WATERFALLDutch Pancreatitis Study Group
Read evolution